Calidi Biotherapeutics (CLDI) Equity Average (2022 - 2025)
Calidi Biotherapeutics' quarterly Equity Average came in at $5.5 million in Q4 2025, up 239.94% year-on-year from $1.6 million in Q4 2024, and up 18.15% quarter-over-quarter from $4.6 million in Q3 2025.
Calidi Biotherapeutics has reported Equity Average for 4 years, with the latest figure at $5.5 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 239.94% year-over-year to $5.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.5 million (up 239.94% YoY), and the FY2025 full-year result was $2.9 million, up 191.38% from the prior year.
- Equity Average for Q4 2025 stood at $5.5 million, up from $4.6 million in the prior quarter.
- The five-year high for Equity Average was $5.5 million in Q4 2025, with the low at -$59.4 million in Q2 2023.
- Average Equity Average over 4 years is -$20.7 million, with a median of -$12.3 million recorded in 2024.
- Year-over-year, Equity Average slumped 53.77% in 2023 and soared 239.94% in 2025.
- Tracing CLDI's Equity Average over 4 years: stood at -$47.2 million in 2022, then jumped by 90.11% to -$4.7 million in 2023, then grew by 16.07% to -$3.9 million in 2024, then soared by 239.94% to $5.5 million in 2025.
- The last three Equity Average figures came in at $5.5 million (Q4 2025), $4.6 million (Q3 2025), and $4.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 31.34 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 5.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.48 Mn |
| Sep 30, 2025 | 4.64 Mn |
| Jun 30, 2025 | 4.69 Mn |
| Mar 31, 2025 | 4.63 Mn |
| Dec 31, 2024 | -3.92 Mn |
| Sep 30, 2024 | -10.78 Mn |
| Jun 30, 2024 | -13.16 Mn |
| Mar 31, 2024 | -11.40 Mn |
| Dec 31, 2023 | -4.66 Mn |
| Sep 30, 2023 | -32.40 Mn |
| Jun 30, 2023 | -59.40 Mn |
| Mar 31, 2023 | -52.77 Mn |
| Dec 31, 2022 | -47.18 Mn |
| Sep 30, 2022 | -41.78 Mn |
| Jun 30, 2022 | -38.63 Mn |
| Mar 31, 2022 | -34.62 Mn |